ANP, BNP, and CNP form a natural cardiovascular defense system, and neprilysin inhibition (sacubitril/valsartan) represents a successful strategy to enhance their protective effects.
3 natural defendersANP, BNP, and CNP form the heart's natural blood pressure defense — neprilysin inhibition enhances all three
What the researchers found
ANP and BNP are released by the heart in response to increased pressure or volume. They lower blood pressure and reduce fluid retention through specific receptors. CNP is produced by blood vessel walls and acts locally to protect blood vessels.
Beyond lowering blood pressure, natriuretic peptides also reduce the organ damage caused by hypertension, including heart enlargement, kidney damage, and blood vessel stiffening.
Neprilysin is the enzyme that degrades natriuretic peptides. Blocking neprilysin with drugs increases the activity of the body's own peptides. A dual inhibitor combining neprilysin inhibition with an angiotensin receptor blocker (sacubitril/valsartan) has been approved for heart failure, and clinical data shows neprilysin inhibition also benefits hypertension patients.
Why it matters
High blood pressure is the leading risk factor for heart disease and stroke worldwide. The natriuretic peptide system represents a natural defense mechanism that the body uses to fight elevated blood pressure. Drugs that enhance this system, rather than simply blocking harmful pathways, offer a fundamentally different approach to treatment.
The approval of sacubitril/valsartan for heart failure has already validated this approach, and expanding its use to hypertension could benefit millions of patients.
The numbers in context
3 natriuretic peptides (ANP, BNP, CNP); sacubitril/valsartan approved for heart failure; neprilysin inhibition beneficial in hypertension
How the study worked
This is a comprehensive review article summarizing basic science and clinical research on natriuretic peptides in blood pressure regulation, hypertensive organ damage, and the therapeutic potential of neprilysin inhibition.
Who was studied
N/A (literature review)
What this study cannot tell us
As a review article, this does not present new experimental data. The coverage of neprilysin inhibition for hypertension is based on limited clinical data compared to the robust heart failure evidence.
The review may not include the most recent clinical trial results published after its writing.
How to read the evidence
Strong evidence for heart failure (approved drug). Moderate evidence for hypertension (ongoing research).
When this study was published
Published in 2020. Sacubitril/valsartan is now widely prescribed for heart failure with reduced ejection fraction.
The bigger picture
Hypertension is the leading risk factor for heart disease and stroke worldwide. The natriuretic peptide system is the body's built-in defense. Drugs that boost this system (neprilysin inhibitors) represent a paradigm shift from blocking harmful pathways to enhancing protective ones.
Questions still open
- Will neprilysin inhibition become standard for hypertension beyond heart failure?
- Can CNP-enhancing strategies provide additional vascular protection?
- What are the long-term effects of chronically elevated natriuretic peptide levels?
Common questions
What do natriuretic peptides do?
How does sacubitril/valsartan work?
Read the original research
Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.
Peptides, 132, 170352
Citation
Kato, Johji. (2020). Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.. Peptides, 132, 170352. https://doi.org/10.1016/j.peptides.2020.170352